Clinical trial
Sunitinib in Refractory Adrenocortical Carcinoma
NCT00453895 · University of Wuerzburg, Other · Completed
Key facts
| NCT number | NCT00453895 |
|---|---|
| Title | Sunitinib in Refractory Adrenocortical Carcinoma |
| Official title | Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy |
| Acronym | SIRAC |
| Lead sponsor | University of Wuerzburg, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adrenocortical Carcinoma |
| Intervention type | Drug |
| Interventions | Sunitinib |
| Enrollment | 39 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2011 |
| Completion | Feb 1, 2012 |
| First posted | Mar 29, 2007 |
| Last update posted | Jan 31, 2019 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: